2-bromo-6-[(2-tetrahydro-2H-pyranyloxy)methyl]pyridine | 149775-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-bromo-6-[(2-tetrahydro-2H-pyranyloxy)methyl]pyridine
• 英文别名: 2-bromo-6-((tetrahydro-2H-pyran-2-yloxy)methyl)pyridine；6-bromo-2-[(tetrahydropyran-2-yl)oxymethyl]pyridine；2-bromo-6-(oxan-2-yloxymethyl)pyridine
• CAS: 149775-50-8
• 化学式: C₁₁H₁₄BrNO₂
• 分子量: 272.142
• InChiKey: YMDKQGMLXQUFKH-UHFFFAOYSA-N

物化性质

• 沸点：
  353.2±42.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-6-[(2-tetrahydro-2H-pyranyloxy)methyl]pyridine 在 盐酸 、 四(三苯基膦)钯 、 正丁基锂 、 三溴化磷 、 copper(I) bromide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 4.75h， 生成 6,6''-bis(bromomethyl)-2,2':6',2''-terpyridine
  参考文献：
  名称：

  合成和大环镧系元素（的光学性质III）螯合物作为发光生物标记新试剂†

  摘要：

  基于二吡啶基6,7,8,9-四氢吩嗪（dpqc）或2,2'：6'，2''-三联吡啶（tpy）的两个大环配体（15和18元）的便捷高效合成描述了杂环和DTTA（二亚乙基三胺三乙酸）骨架。在这些配体中，DTTA骨架包含一个额外的环外官能团（NH 2基团），适合于共价附接到生物活性分子上。这些八齿和九齿配体在生理pH下在水溶液中形成非常稳定且发光的中性镧系元素络合物。相应的Eu（III）和Tb（III配合物的特征在于与氮激光激发（337 nm）兼容的最大吸收波长以及有吸引力的寿命和量子产率。研究了在Eu（III）配合物中进一步引入马来酰亚胺可生物缀合的手柄，并使用相应的Eu（III）tpy衍生物在337 nm处获得了1500 dm 3 mol -1 cm -1以上的有价值的发光亮度。最后，将这两种发光螯合物嫁接到模型抗体（Mab GSS11）的硫醇残基上，而不会丧失其发光特性。

  DOI：

  10.1039/c2ob26311d
• 作为产物：
  描述：

  2-溴-6-甲基吡啶 在 chromium(VI) oxide 、 sodium tetrahydroborate 、 硫酸 、 对甲苯磺酸 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 1.0h， 生成 2-bromo-6-[(2-tetrahydro-2H-pyranyloxy)methyl]pyridine
  参考文献：
  名称：

  Double Subroutine Self-Assembly; Spontaneous Generation of a Nanocyclic Dodecanuclear Cu1 Inorganic Architecture

  摘要：

  AbstractThe newly synthesised ligand 2 combines binding components known to undergo specific and distinct self‐assembly processes with Cu1 ions. It complexes Cu1 to form, in almost quantitative yield, a large inorganic architecture 1 made up from four ligand molecules and twelve metal ions. The structure of 1 was ascertained by X‐ray radiocrystallography as well as by NMR spectroscopy and electrospray mass spectrometry. It consists of a macrocycle of nanometric dimension with an external diameter of 28 Å; the central cavity has a diameter of 11 Å, which contains four PF−6 anions as well as solvent molecules. The spontaneous formation of 1 results from a self‐assembly process based on a “program” combining two assembly subroutines, each specific to one of the ligand subunits. Self‐assembly through double or, more generally, multiple subroutines can be used to generate a wide variety of highly complex inorganic supramolecular architectures by combination of two or more assembly processes.

  DOI：

  10.1002/chem.19970030116

文献信息

• [EN] ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT UN GROUPE HÉTÉROCYCLIQUE SUPPLÉMENTAIRE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2009145718A1

  公开（公告）日：2009-12-03

  Compounds of formula I are claimed, wherein R1is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; wherein C1-3alkyl may optionally be substituted by one or more substituents independently selected from hydroxy, C1-3alkoxy orfluoro; and wherein Ci^alkoxy may optionally be substituted by one or more fluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, C1_4haloalkoxy, halo, C1_4alkoxy, C1_4alkyl and C3_7cycloalkyloxy; and wherein said C3_7cycloalkyloxy may optionally be substituted by one or more fluoro; and whereas both R2 and R3 can not be hydrogen; Het is selected from any one of pyridinyl, pyrazinyl, isoxazolyl, pyrazolyl, indolyl, triazolyl and pyrimidinyl, wherein each such heteroaryl may optionally be substituted by one or more X4; X4 is halo, C1-3alkyl, C1-3alkyl0C1-3alkyl, -CH(CH3)-O-C(CH3)3,C1_4alkoxy, cyano, or hydroxyl, or Ci_2hydroxyalkyl;; and wherein said C1-3alkyl, C 1-3alkylOC1-3alkyl, -CH(CH3)-O-C(CH3)3, or C1_4alkoxy may each optionally be substituted by one or more fluoro; L1 is C1_4alkylene, which may optionally be fluorinated or hydroxylated; and L2 is C1-3alkylene; with the exception of the compounds: 2-[1-(1,5-dimethyl-lH-pyrazol-4-yl)ethyl]-5,7-dimethoxy-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-1-carboxamide; N-(4-fluorobenzyl)-3-oxo-2-(-pyridin-4-yletyl)isoindoline-1-carboxamide and N-(2-chlorobenzyl)-2[2-(1H-indol-3-yl)-1-methyletyl]-3-oxoisoindoline-1-carboxamide; The invention further relates to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  公式I的化合物被要求，其中R1是氢，C1-3烷基，C1-3烷氧基，氰基，羟基或卤素；其中C1-3烷基可以选择性地被一个或多个取代基取代，这些取代基独立地选自羟基，C1-3烷氧基或氟基；而C1-3烷氧基可以选择性地被一个或多个氟基取代；m为1或2；R2和R3分别且独立地选自氢，C1-4卤代烷基，C1-4卤代烷氧基，卤素，C1-4烷氧基，C1-4烷基和C3-7环烷氧基；其中所述的C3-7环烷氧基可以选择性地被一个或多个氟基取代；而且R2和R3都不能是氢；Het选自吡啶基，吡嗪基，异噁唑基，吡唑基，吲哚基，三唑基和嘧啶基中的任何一种，其中每种这样的杂环烷基可以选择性地被一个或多个X4取代；X4是卤素，C1-3烷基，C1-3烷氧基C1-3烷基，-CH(CH3)-O-C(CH3)3，C1-4烷氧基，氰基，或羟基，或C1-2羟基烷基；而所述的C1-3烷基，C1-3烷氧基C1-3烷基，-CH(CH3)-O-C(CH3)3，或C1-4烷氧基可以选择性地被一个或多个氟基取代；L1是C1-4烷基，可以选择性地被氟化或羟基化；而L2是C1-3烷基；除了以下化合物：2-[1-(1,5-二甲基-1H-吡唑-4-基)乙基]-5,7-二甲氧基-3-氧代-N-[2-(三氟甲基)苯甲基]异吲哚啉-1-羧酰胺；N-(4-氟苯甲基)-3-氧代-2-(-吡啶-4-基乙基)异吲哚啉-1-羧酰胺和N-(2-氯苯甲基)-2[2-(1H-吲哚-3-基)-1-甲基乙基]-3-氧代异吲哚啉-1-羧酰胺；本发明还涉及含有所述化合物的药物组合物以及所述化合物在治疗中的使用。
• Substituted 1,2,4-triazolo&lsqb;3,4-a&rsqb;phthalazine derivatives as GABA alpha 5 ligands
  申请人：Merck Sharp & Dohme Limited

  公开号：US06200975B1

  公开（公告）日：2001-03-13

  Substituted 1,2,4-Triazolo[3,4-A]phthalazine derivatives are GABA Alpha 5 ligands and are represented by the formula

  取代的1,2,4-三氮唑[3,4-A]邻苯二氮杂环衍生物是GABA Alpha 5配体，其化学式表示为
• Precursor compounds to substituted 1,2,4-triazolo&lsqb;3,4,-a&rsqb;phathalazine GABA alpha 5 ligands
  申请人：Merck Sharpe & Dohme Limited

  公开号：US06310203B1

  公开（公告）日：2001-10-30

  Substituted 1,2,4-Triazolo[3,4-A]phthalazine derivatives that are GABA Alpha 5 ligands are prepared from compounds represented by the formula: in which R1 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; R2 is hydrogen, halogen, CF3, OCF3, CN or an optionally substituted C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy group; Z is an optionally substituted 5-membered or 6-membered heteroaromatic ring; and G is a leaving group.

  制备了替代1,2,4-三唑并[3,4-A]鞣酸衍生物，这些衍生物是GABA Alpha 5配体，其由以下式子所代表的化合物制备而来：其中R1为氢、卤素、CF3、OCF3、CN或可选择取代的C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C2-4烯氧基或C2-4炔氧基；R2为氢、卤素、CF3、OCF3、CN或可选择取代的C1-4烷基、C2-4烯基、C2-4炔基、C1-4烷氧基、C2-4烯氧基或C2-4炔氧基；Z为可选择取代的5元或6元杂环芳香环；G为离去基团。
• Meth-Cohn, Otto; Jiang, Hui, Journal of the Chemical Society. Perkin transactions I, 1998, # 22, p. 3737 - 3745
  作者：Meth-Cohn, Otto、Jiang, Hui

  DOI：——

  日期：——
• Synthesis of ι-(bromomethyl)bipyridines and related ι-(bromomethyl)pyridinoheteroaromatics: useful functional tools for ligands in host molecules
  作者：Junichi Uenishi、Takakazu Tanaka、Kenji Nishiwaki、Shoji Wakabayashi、Shigeru Oae、Hiroshi Tsukube

  DOI：10.1021/jo00068a037

  日期：1993.7

  Pyridines and 2,2'-bipyridines have been employed as useful ligands in molecular recognition chemistries. Halomethyl-substituted bipyridine or oligopyridine derivatives were required for the assembly of bipyridine or oligopyridine units with a supporting mother functional part in artificial biofunctional molecules. A series of omega-(bromomethyl)bipyridines and related omega-(bromomethyl)pyridinoheteroaromatic compounds (types I-III) were synthesized in this paper. Preparation of oligopyridines and pyridinoheteroaromatic compounds have been carried out by either intermolecular ligand coupling of alkyl heteroaryl sulfoxide with pyridyllithium or intramolecular ligand coupling of pyridyl heteroaryl sulfoxide with methylmagnesium bromide for the type I compounds. The type II and III compounds were synthesized by addition of pyridyllithium to pyridinecarboxaldehyde. The omega-bromo group was introduced by radical bromination reaction of methylpyridyl group using NBS and BPO (dibenzoyl peroxide) or bromination of omega-(hydroxymethyl)pyridine using a combination of CBr4 and Ph3P.